DGIdb - LOVASTATIN Drug Record

LOVASTATIN chembl:CHEMBL503 ApprovedAntineoplastic

Alternate Names:

MEVINACOR 10
SIMVASTATIN IMPURITY, LOVASTATIN-
L-154803
MEVINOLIN
MEVACOR
MEVINACOR
MK-803
ALTOPREV
MEVINACOR 40
LOVASTATIN
C10AA02
6-ALPHA-METHYLCOMPACTIN
(1S,3R,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(2R,4R)-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL (S)-2-METHYL-BUTYRATE
2Β,6Α-DIMETHYL-8ALPHA-(2-METHYL-1-OXOBUTOXY)-MEVINIC ACID LACTONE
LOVASTATINA
LOVASTATINUM
6ALPHA-METHYLCOMPACTIN
LOVASTATINE
6Α-METHYLCOMPACTIN
chemidplus:75330-75-5
pubchem.compound:53232
rxcui:6472
drugbank:00227
chembl:CHEMBL503

Drug Info:

Year of Approval	1987
Drug Class	anticholesteremic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	anticholesterolaemic agent

(5 More Sources)

Publications:

Pau et al., Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells., Biochem. Cell Biol.
Arad et al., 1990, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production., J. Lipid Res.
Arad et al., 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins., Metab. Clin. Exp.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Yin OQ et al., 2012, Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects., Eur J Clin Pharmacol
Buxbaum et al., 2001, Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide., J. Alzheimers Dis.
Farina et al., 2002, Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells., Clin. Exp. Metastasis
Podar et al., 2009, Emerging therapies for multiple myeloma., Expert Opin Emerg Drugs
Baranova et al., 2002, [Concentration on Diapak C 16 capsules of lovastatin, mevinolinic acid and other inhibitors of biosynthesis of sterins produced by Penicillium citrinum 89]., Antibiot. Khimioter.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Abe et al., 2002, Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum., Mol. Genet. Genomics
Miyazaki et al., 2002, Effects of pravastatin sodium on mevalonate metabolism in common marmosets., J. Biochem.
Dimitroulakos et al., Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas., Neoplasia
Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem
Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
Iwama et al., 1995, Effect of lovastatin and fluoromevalonate on phosphatidylinositol 3-kinase activity stimulated with PDGF., Clin Exp Pharmacol Physiol Suppl
Hung et al., 1999, Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol., J. Formos. Med. Assoc.
Prasad et al., 2005, Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction., J. Neurochem.
Kaneko R et al., 2007, Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer., J Biol Chem
Ledoux et al., 2002, Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases., Circ. Res.
Camarillo et al., 1997, Lovastatin inhibits prolactin-induced Nb2 cell mitogenesis and milk product synthesis in mouse mammary gland explants., Proc. Soc. Exp. Biol. Med.
Medh et al., 1996, Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro., J. Biol. Chem.
Rassoul et al., 2001, Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease., Int J Clin Pharmacol Ther
Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
Kim et al., 1999, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein., Pharm. Res.
Hansen et al., 1995, Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia., Arterioscler. Thromb. Vasc. Biol.
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
Jiang et al., 1993, Transcriptional regulation by lovastatin and 25-hydroxycholesterol in HepG2 cells and molecular cloning and expression of the cDNA for the human hepatic squalene synthase., J. Biol. Chem.
Hsu MH et al., 2007, Regulation of human cytochrome P450 4F2 expression by sterol regulatory element-binding protein and lovastatin., J Biol Chem
Tirkkonen et al., 2008, Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study., Drug Saf
Ohno et al., 2007, General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs., Clin Pharmacokinet
Riessen et al., 1999, Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells., Basic Res. Cardiol.
Maddala et al., 2001, Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPases., Invest. Ophthalmol. Vis. Sci.
Esfahani et al., 1993, Effect of lovastatin on cell surface expression of Fc receptors or CD14 antigen in human monocytes., Biochem. Pharmacol.
Tornio A et al., 2015, SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid., Pharmacogenet Genomics
Hsiang B et al., 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters., J Biol Chem
Lee et al., 1998, Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells., J. Biol. Chem.
Kam et al., 1990, Effect of lovastatin on acyl-CoA: cholesterol O-acyltransferase (ACAT) activity and the basolateral-membrane secretion of newly synthesized lipids by CaCo-2 cells., Biochem. J.

LOVASTATIN HMGCR

Interaction Score: 1.66

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name lovastatin,Mevacor, Altocor, Altoprev

Novel drug target Established target

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031

Sources:
DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND PharmGKB TTD
LOVASTATIN CD14

Interaction Score: 1.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7506029

Sources:
NCI
LOVASTATIN PXN

Interaction Score: 1.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11581207

Sources:
NCI
LOVASTATIN FDFT1

Interaction Score: 1.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7685352

Sources:
NCI
LOVASTATIN APOA5

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19530961

Sources:
PharmGKB
LOVASTATIN SOAT1

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2268271

Sources:
NCI
LOVASTATIN LIPA

Interaction Score: 0.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11380065

Sources:
NCI
LOVASTATIN THBS1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10543307

Sources:
NCI
LOVASTATIN CYP4F2

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17142457

Sources:
PharmGKB
LOVASTATIN APOB

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7662319 2351867 1588827

Sources:
NCI
LOVASTATIN TFPI

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7600119

Sources:
NCI
LOVASTATIN CETP

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896

Sources:
PharmGKB
LOVASTATIN NT5E

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11884371

Sources:
NCI
LOVASTATIN LEP

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10083765

Sources:
NCI
LOVASTATIN LPL

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8663292

Sources:
NCI
LOVASTATIN SLCO1B1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26020121 16103896 10601278 15616150

Sources:
PharmGKB
LOVASTATIN LDLR

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896

Sources:
PharmGKB
LOVASTATIN UGT1A3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN PRL

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9316617

Sources:
NCI
LOVASTATIN SLCO2B1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN SLCO1B3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN UGT2B7

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN CYP2C8

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN PIK3CB

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9072409

Sources:
NCI
LOVASTATIN PIK3CG

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9072409 15953363

Sources:
NCI
LOVASTATIN CDK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9553123

Sources:
NCI
LOVASTATIN CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978 15284534

Sources:
PharmGKB
LOVASTATIN AKT1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17472962

Sources:
DTC
LOVASTATIN UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN ABCC2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15616150 10213372

Sources:
NCI PharmGKB
LOVASTATIN RORC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LOVASTATIN NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOVASTATIN SMN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LOVASTATIN SMN1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LOVASTATIN CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
LOVASTATIN CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 22281720

Sources:
DTC PharmGKB
LOVASTATIN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 18302447 17655375

Sources:
DTC NCI PharmGKB
LOVASTATIN CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
LOVASTATIN CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
LOVASTATIN IDH1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LOVASTATIN VDR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LOVASTATIN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: LOVASTATIN
- Version: 01-August-2011
Alternate Names:

LOVASTATIN Primary Drug Name

Drug Info:

Drug Class anticholesteremic agents

Year of Approval 1987

Publications:
TdgClinicalTrial: LOVASTATIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications anticholesterolaemic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: LOVASTATIN

Version: 14-September-2017

Alternate Names:

C620 NCI drug code

Drug Info:

Publications:

Arad et al., 1990, Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production., J. Lipid Res.

Pau et al., Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells., Biochem. Cell Biol.

Arad et al., 1992, Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins., Metab. Clin. Exp.

DTC: LOVASTATIN

Version: 02-September-2020

Alternate Names:

CHEMBL503 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Kaneko R et al., 2007, Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer., J Biol Chem

Zhou X et al., 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., Bioorg Med Chem

PharmGKB: lovastatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics

Yin OQ et al., 2012, Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects., Eur J Clin Pharmacol

TTD: Lovastatin
- Version: 2020.06.01
Alternate Names:

D06WTZ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL503
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: LOVASTATIN
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL503
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	lovastatin,Mevacor, Altocor, Altoprev
Novel drug target	Established target
Mechanism of Interaction	HMG-CoA reductase inhibitor

LOVASTATIN Drug Record

LOVASTATIN chembl:CHEMBL503 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name lovastatin,Mevacor, Altocor, Altoprev Novel drug target Established target Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs: 12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031

Sources: DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7506029

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11581207

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7685352

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19530961

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2268271

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11380065

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10543307

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17142457

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7662319 2351867 1588827

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7600119

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11884371

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10083765

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8663292

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26020121 16103896 10601278 15616150

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9316617

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name lovastatin,Mevacor, Altocor, Altoprev

Novel drug target Established target

Mechanism of Interaction HMG-CoA reductase inhibitor

PMIDs:
12214063 12405293 19249983 12369143 11752352 12172803 12204108 12082550 24726306 17563401 18815589 18332269 16103896 18261733 15199031

Sources:
DTC TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
7506029

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11581207

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7685352

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19530961

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
2268271

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11380065

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10543307

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17142457

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
7662319 2351867 1588827

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7600119

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16103896

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11884371

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10083765

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8663292

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
26020121 16103896 10601278 15616150

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16103896

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9316617

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9072409

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9072409 15953363

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9553123

Sources:
NCI

Interaction Types & Directionality:

n/a